Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Analysis

Editor-in-Chief

ISSN (Print): 1573-4129
ISSN (Online): 1875-676X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Determination of Tyrosine Kinase Inhibitor Icotinib in Rat Plasma using UPLC-MS/MS and its Application In vivo Pharmacokinetic

Author(s): Xuewei Zhao, Ruoyang Li, Zhangying Feng, Shanshan Chen, Yu Liang, Jinglin Gao and Mingxia Wang*

Volume 20, Issue 1, 2024

Published on: 25 January, 2024

Page: [76 - 84] Pages: 9

DOI: 10.2174/0115734129276657231130055912

Price: $65

conference banner
Abstract

Objective: The purpose of this study was to develop a UPLC-MS/MS method for the determination of icotinib concentrations in blood plasma.

Methods: For plasma sample preparation, protein precipitation with acetonitrile was utilized. Analytes were separated on a Kinetex C18 column using 10 mM ammonium acetate containing 0.2% formic acid and methanol (30:70) as the mobile phase, with a gradient flow rate ranging from 0.2 ml·min-1 to 0.4 ml·min-1. The total chromatographic analysis duration was 4.5 minutes. The UPLC system was connected to a mass spectrometer via an electrospray ionization (ESI) interface operated in positive ion mode. Mass monitoring was conducted in multiple reaction monitoring (MRM) modes, with precursor-to-product transitions being m/z 392.06→304.07 for icotinib and m/z 248.00→120.09 for the internal standard, tinidazole. This method has been used for a pharmacokinetic study in rats that were orally administered a single dose of 30 mg/kg icotinib.

Results: The assay showed good linearity over concentration ranges of 1-1000 ng/ml for icotinib, with the correlation coefficient exceeding 0.99. The lower limit of quantitation (LLOQ) was established at 1 ng/ml. Both intra- and inter-day precisions (RSD, %) were below 8.23%. The results demonstrated that stability, matrix effect, extraction recovery, carryover effect and dilution stability were all within the acceptable conditions. The primary pharmacokinetic parameters in SD rats after oral administration of icotinib (30 mg·kg-1) were as follows: t1/2 = (2.92 ± 0.87)h, Cmax = (2168.65 ± 268.72)ng/ml, Tmax = (0.70 ± 0.27)h, AUC=(9.69 ± 1.95)ug/mL•h, Vd = (14.51 ± 5.60)L, and CL = (3.19 ± 0.59)L/h.

Conclusion: A simple and sensitive UPLC-MS/MS method was developed and validated for the determination of icotinib in pharmacokinetic studies.

« Previous
Graphical Abstract

[1]
Sun, X.; Niu, L.; Li, X.; Lu, X.; Li, F. Characterization of metabolic profile of mosapride citrate in rat and identification of two new metabolites: Mosapride N-oxide and morpholine ring-opened mosapride by UPLC–ESI-MS/MS. J. Pharm. Biomed. Anal., 2009, 50(1), 27-34.
[http://dx.doi.org/10.1016/j.jpba.2009.03.011] [PMID: 19362796]
[2]
Mitsudomi, T.; Yatabe, Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci., 2007, 98(12), 1817-1824.
[http://dx.doi.org/10.1111/j.1349-7006.2007.00607.x] [PMID: 17888036]
[3]
Chen, J.; Zheng, X.; Liu, D.Y.; Zhao, Q.; Wu, Y.W.; Tan, F.L.; Wang, Y.X.; Jiang, J.; Hu, P. Therapeutic effects and adverse drug reactions are affected by icotinib exposure and CYP2C19 and EGFR genotypes in Chinese non-small cell lung cancer patients. Asian Pac. J. Cancer Prev., 2014, 15(17), 7195-7200.
[http://dx.doi.org/10.7314/APJCP.2014.15.17.7195] [PMID: 25227813]
[4]
Li, J.; Zhao, M.; He, P.; Hidalgo, M.; Baker, S.D. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin. Cancer Res., 2007, 13(12), 3731-3737.
[http://dx.doi.org/10.1158/1078-0432.CCR-07-0088] [PMID: 17575239]
[5]
Xu, L.; Qi, Q.; Zhang, Y.; Cui, J.; Liu, R.; Li, Y. Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A randomized controlled study. Lung Cancer, 2019, 133, 23-31.
[http://dx.doi.org/10.1016/j.lungcan.2019.05.008] [PMID: 31200823]
[6]
Wang, H.P.; Zhang, L.; Wang, Y.X.; Tan, F.L.; Xia, Y.; Ren, G.J.; Hu, P.; Jiang, J.; Wang, M.Z.; Xiao, Y. Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer. Chin. Med. J., 2011, 124(13), 1933.
[PMID: 22088449]
[7]
Huang, J.; Fan, Q.; Lu, P.; Ying, J.; Ma, C.; Liu, W.; Liu, Y.; Tan, F.; Sun, Y. Icotinib in patients with pretreated, advanced esophageal squamous cell carcinoma with EGFR overexpression or EGFR gene amplification: A single-arm, multicenter, phase 2 study. J. Thorac. Oncol., 2016, 11(6), 910-917.
[http://dx.doi.org/10.1016/j.jtho.2016.02.020] [PMID: 26980473]
[8]
Liu, D.; Jiang, J.; Hu, P.; Tan, F.; Wang, Y. Quantitative determination of icotinib in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2009, 877(30), 3781-3786.
[http://dx.doi.org/10.1016/j.jchromb.2009.08.055] [PMID: 19833564]
[9]
Xiao, Y.; Maiolino, P.; Yan, J.H.; Ma, J.; Li, J.; Chen, L. Validation of an LC‐MS/MS method for simultaneous determination of icotinib and its four major circulating metabolites in human plasma and its application in a pharmacokinetic study. Biomed. Chromatogr., 2018, 32(11), e4327.
[http://dx.doi.org/10.1002/bmc.4327] [PMID: 29975793]
[10]
Guan, Z.M.; Chen, X.Y.; Zhong, D.F. Pharmacokinetics of icotinib in Beagle dog studied by using LC/MS/MS method. Chinese. J Clini. Pharma. & Therap., 2008, 2008, 47-49.
[11]
Ezzeldin, E.; Iqbal, M.; Al-Salahi, R.; El-Nahhas, T. Development and validation of a UPLC-MS/MS method for determination of motesanib in plasma: Application to metabolic stability and pharmacokinetic studies in rats. J. Pharm. Biomed. Anal., 2019, 166, 244-251.
[http://dx.doi.org/10.1016/j.jpba.2019.01.023] [PMID: 30665192]
[12]
Siddiqui, M.R.; AlOthman, Z.A.; Rahman, N. Analytical techniques in pharmaceutical analysis: A review. Arab. J. Chem., 2017, 10, S1409-S1421.
[http://dx.doi.org/10.1016/j.arabjc.2013.04.016]
[13]
Alothman, Z.; Rahman, N.; Siddiqui, M.R. Review on pharmaceutical impurities, stability studies and degradation products: An analytical approach. Rev. Adv. Sci. Eng., 2013, 2(2), 155-166.
[http://dx.doi.org/10.1166/rase.2013.1039]
[14]
Rahman, N.; Azmi, S.N.H.; Wu, H.F. The importance of impurity analysis in pharmaceutical products: An integrated approach. Accredit. Qual. Assur., 2006, 11(1-2), 69-74.
[http://dx.doi.org/10.1007/s00769-006-0095-y]
[15]
Husain, A.; Iram, F.; Siddiqui, A.A.; Almutairi, S.M.; Mohammed, O.B.; Khan, S.A.; Azmi, S.N.H.; Rahman, N. Identification of metabolic pathways involved in the biotransformation of eslicarbazepine acetate using UPLC-MS/MS, human microsomal enzymes and in silico studies. J. King Saud Univ. Sci., 2021, 33(2), 101281.
[http://dx.doi.org/10.1016/j.jksus.2020.101281]
[16]
China Pharmacopoeia Committee. Pharmacopoeia of People’s Republic of China; Chemical Industry Press: Beijing, 2015, 3, pp. 302-303.
[17]
Gao, J.; Feng, Z.; Ren, H.; Yu, M.; Wang, H.; Wang, M. A rapid and selective UPLC-MS/MS assay for accurate analysis of apatinib in rat plasma and its application to a pharmacokinetic study. Curr. Pharm. Anal., 2021, 17(5), 594-602.
[http://dx.doi.org/10.2174/1573412916666200206143836]
[18]
Tan, F.L.; Zhang, L.; Zhao, Q.; Liu, D.Y.; Hu, Y.; Liu, Y.; Hu, B. Pharmaocology and clinical evaluation of icotinib hydrochloride. Zhongguo Xin Yao Zazhi, 2009, 18(18), 1-4.
[19]
Ni, J.; Liu, D.Y.; Hu, B.; Li, C.; Jiang, J.; Wang, H.P.; Zhang, L. Relationship between icotinib hydrochloride exposure and clinical outcome in Chinese patients with advanced non–small cell lung cancer. Cancer, 2015, 121(S17), 3146-3156.
[http://dx.doi.org/10.1002/cncr.29568] [PMID: 26331821]
[20]
Liu, D.; Jiang, J.; Zhang, L.; Tan, F.; Wang, Y.; Zhang, D.; Hu, P. Clinical pharmacokinetics of Icotinib, an anti-cancer drug: evaluation of dose proportionality, food effect, and tolerability in healthy subjects. Cancer Chemother. Pharmacol., 2014, 73(4), 721-727.
[http://dx.doi.org/10.1007/s00280-014-2398-8] [PMID: 24488324]
[21]
Zhou, L.; He, J.; Xiong, W.; Liu, Y.; Xiang, J.; Yu, Q.; Liang, M.; Zhou, X.; Ding, Z.; Huang, M.; Ren, L.; Zhu, J.; Li, L.; Hou, M.; Ding, L.; Tan, F.; Lu, Y. Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study. Lung Cancer, 2016, 96, 93-100.
[http://dx.doi.org/10.1016/j.lungcan.2016.04.003] [PMID: 27133757]
[22]
Zhao, Q.; Shentu, J.; Xu, N.; Zhou, J.; Yang, G.; Yao, Y.; Tan, F.; Liu, D.; Wang, Y.; Zhou, J. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer, 2011, 73(2), 195-202.
[http://dx.doi.org/10.1016/j.lungcan.2010.11.007] [PMID: 21144613]
[23]
Liu, D.; Zhang, L.; Wu, Y.; Jiang, J.; Tan, F.; Wang, Y.; Liu, Y.; Hu, P. Clinical pharmacokinetics, safety, and preliminary efficacy evaluation of icotinib in patients with advanced non-small cell lung cancer. Lung Cancer, 2015, 89(3), 262-267.
[http://dx.doi.org/10.1016/j.lungcan.2015.05.024] [PMID: 26162563]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy